A Phase 2, Randomized, Vehicle-Controlled, Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of Three Once-Daily CLS001 Topical Gels Versus Vehicle Administered for 12 Weeks to Subjects With Papulopustular Rosacea

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Outcome Measure:

Change in inflammatory lesion count

Outcome Time Frame:

0, 1, 3, 6, 9 and 12 weeks

Safety Issue:

No

Authority:

United States: Food and Drug Administration

Study ID:

CLS001-CO-PR-001

NCT ID:

NCT01784133

Start Date:

March 2013

Completion Date:

Related Keywords:

• Papulopustular Rosacea
• rosacea
• Rosacea